Literature DB >> 1156513

Assay of anti-cancer drugs in tissue culture: conditions affecting their ability to incorporate 3H-leucine after drug treatment.

R I Freshney, J Paul, I M Kane.   

Abstract

An attempt has been made to construct an assay potentially suitable for use with primary cultures of human tumours to measure the survival of exponentially growing monolayer cultures after exposure to anti-neoplastic drugs. Cell survival was assessed using their protein synthetic capacity after removal of drugs. HeLa cells were employed to avoid the ingerent variability and heterogeneity of primary cultures from human tumours, and an assay has been constructed using microtitration trays to provide large numbers of replicate cultures without the requirement of a large number cells. An increase in the duration of the exposure to drug increased sensitivity in nearly all cases examined. Similarly, an increase in the period of culture following drug removal produced increased sensitivity to alkylating agents but allowed recovery from exposure to certain cycle-dependent drugs. Some of the drugs used were shown to be unstable under culture conditions and vinblastine was actively metabolized, although this instability was not necessarily reflected in the time course of the drug's effect. Mustine sensitivity was shown to be reduced by an increase in cell density at a level where density limitation of 3H-thymidine incorporation becomes apparent. These variations and possible methods of minimizing their effects are discussed.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1156513      PMCID: PMC2009346          DOI: 10.1038/bjc.1975.11

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  9 in total

1.  Bioassay and relative cytotoxic potency of cyclophosphamide metabolites generated in vitro and in vivo.

Authors:  N E Sladek
Journal:  Cancer Res       Date:  1973-06       Impact factor: 12.701

2.  Method for tissue culture evaluation of the cytoxic activity of drugs active through the formation of metabolites.

Authors:  E Dolfini; A Martini; M G Donnelli; L Morasca; S Garattini
Journal:  Eur J Cancer       Date:  1973-05       Impact factor: 9.162

3.  Effects of methotrexate on established cell lines of human choriocarcinoma.

Authors:  R O Hussa; R A Pattillo
Journal:  Eur J Cancer       Date:  1972-10       Impact factor: 9.162

4.  Chemotherapy of mouse myeloma: quantitative cell cultures predictive of response in vivo.

Authors:  M Ogawa; D E Bergsagel; E A McCulloch
Journal:  Blood       Date:  1973-01       Impact factor: 22.113

5.  A delayed cytotoxic reaction for 6-mercaptopurine.

Authors:  D M Tidd; S C Kim; K Horakova; A Moriwaki; A R Paterson
Journal:  Cancer Res       Date:  1972-02       Impact factor: 12.701

6.  Chemotherapeutic "fingerprints" of two experimental tumors in vitro.

Authors:  L Morasca; G Balconi; F De Nadai; E Dolfini
Journal:  Eur J Cancer       Date:  1972-08       Impact factor: 9.162

7.  Sensitivity to nitrogen mustard as a function of transport activity and proliferative rate in L5178Y lymphoblasts.

Authors:  G J Goldenberg; R M Lyons; J A Lepp; C L Vanstone
Journal:  Cancer Res       Date:  1971-11       Impact factor: 12.701

8.  Chemotherapy in the treatment of advanced pelvic malignant disease with special reference to ovarian cancer.

Authors:  H Limburg; U Heckmann
Journal:  J Obstet Gynaecol Br Commonw       Date:  1968-12

9.  The interpretation of "split-dose" experiments in mammalian cells after treatment with alkylating agents.

Authors:  M Fox; C W Gilbert; L G Lajtha; A H Nias
Journal:  Chem Biol Interact       Date:  1970-02       Impact factor: 5.192

  9 in total
  20 in total

1.  Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity.

Authors:  G Bernhardt; H Reile; H Birnböck; T Spruss; H Schönenberger
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 2.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. III. Antimetabolites, tubulin-binding agents, platinum drugs, amsacrine, L-asparaginase, interferons, steroids and other miscellaneous antitumor agents.

Authors:  A G Bosanquet
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  A trial of the in vitro sensitivity test of anti-cancer drugs using primary cultured urogenital cancer cells.

Authors:  T Miura; Y Kubota; T Sakuramoto; M Hosaka
Journal:  Urol Res       Date:  1987

4.  Biological considerations in the treatment of early carcinoma of the breast and their role in the selection of therapy.

Authors:  M Baum
Journal:  Ann R Coll Surg Engl       Date:  1980-01       Impact factor: 1.891

5.  Inhibition of protein synthesis, pulmonary localization and pulmonary tumour formation by drug-treated tumour cells as a means of predicting their chemosensitivity.

Authors:  T Lai; B R Stonebridge; J Black; M O Symes
Journal:  Clin Exp Metastasis       Date:  1989 Jul-Aug       Impact factor: 5.150

Review 6.  Predictive testing in cancer chemotherapy. II. In vitro.

Authors:  P H Slee; A T Van Oosterom; E A De Bruijn
Journal:  Pharm Weekbl Sci       Date:  1985-08-23

Review 7.  Role of laboratory chemosensitivity testing in the selection of cancer chemotherapy for individual patients.

Authors:  P J Selby; D Raghavan
Journal:  J Clin Pathol       Date:  1981-05       Impact factor: 3.411

8.  Thiotepa versus Bacille Calmette-Guérin in Non-Muscle Invasive Bladder Cancer.

Authors:  Fatemeh Fallah; Mahdi Fallah; Raheleh Sadat Sajadi Nia
Journal:  Curr Urol       Date:  2012-12-21

Review 9.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. General considerations, the nitrosoureas and alkylating agents.

Authors:  A G Bosanquet
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 10.  In vitro chemosensitivity testing and its clinical application in human gliomas.

Authors:  W K Yung
Journal:  Neurosurg Rev       Date:  1989       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.